PL2107069T3 - Nowe pochodne insuliny - Google Patents

Nowe pochodne insuliny

Info

Publication number
PL2107069T3
PL2107069T3 PL09165072T PL09165072T PL2107069T3 PL 2107069 T3 PL2107069 T3 PL 2107069T3 PL 09165072 T PL09165072 T PL 09165072T PL 09165072 T PL09165072 T PL 09165072T PL 2107069 T3 PL2107069 T3 PL 2107069T3
Authority
PL
Poland
Prior art keywords
insulin derivatives
novel insulin
novel
derivatives
insulin
Prior art date
Application number
PL09165072T
Other languages
English (en)
Polish (pl)
Inventor
Ib Jonassen
Thomas Hoeg-Jensen
Svend Havelund
Ulla Ribel-Madsen
Tagmose Tina Moller
Peter Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL2107069T3 publication Critical patent/PL2107069T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09165072T 2003-08-05 2004-07-22 Nowe pochodne insuliny PL2107069T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives
EP09165072A EP2107069B1 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (1)

Publication Number Publication Date
PL2107069T3 true PL2107069T3 (pl) 2013-06-28

Family

ID=34117520

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09165072T PL2107069T3 (pl) 2003-08-05 2004-07-22 Nowe pochodne insuliny

Country Status (18)

Country Link
US (3) US7615532B2 (Direct)
EP (3) EP2107069B1 (Direct)
JP (1) JP4463814B2 (Direct)
KR (1) KR101159559B1 (Direct)
AU (2) AU2004261353B2 (Direct)
BE (2) BE2013C035I2 (Direct)
BR (1) BRPI0413276B8 (Direct)
CA (1) CA2531988C (Direct)
CY (5) CY1113850T1 (Direct)
FR (2) FR13C0035I2 (Direct)
HU (1) HUS1300033I1 (Direct)
IL (1) IL172980A (Direct)
LU (2) LU92213I2 (Direct)
MX (1) MXPA06001283A (Direct)
NO (5) NO340925B1 (Direct)
PL (1) PL2107069T3 (Direct)
RU (1) RU2518460C2 (Direct)
WO (1) WO2005012347A2 (Direct)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
WO2006082204A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2292653B1 (en) * 2005-02-02 2014-05-21 Novo Nordisk A/S Novel insulin derivatives
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
EP2256129B1 (en) 2006-02-27 2012-05-09 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
ES2553154T3 (es) 2006-05-09 2015-12-04 Novo Nordisk A/S Derivado de la insulina
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2395738T3 (es) 2006-05-09 2013-02-14 Novo Nordisk A/S Derivado de insulina
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
JP5550338B2 (ja) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US20100190706A1 (en) * 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
JP5730569B2 (ja) 2007-08-15 2015-06-10 ノボ・ノルデイスク・エー／エス アシル及びアルキレングリコール部分を有するインスリンアナログ
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
MX2011004357A (es) * 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
US8835379B2 (en) 2009-10-30 2014-09-16 Novo Nordisk A/S Derivatives of CGRP
US20130058999A1 (en) * 2010-01-12 2013-03-07 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
US20130012684A1 (en) 2010-02-16 2013-01-10 Novo Nordisk A/S Purification Method
JP5826772B2 (ja) 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
CA2795091A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
AU2011269000C1 (en) * 2010-06-23 2015-10-08 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
WO2011161083A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
SI2632478T1 (sl) 2010-10-27 2019-11-29 Novo Nordisk As Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih
JP6049625B2 (ja) * 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
US20140031278A1 (en) * 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
MX354705B (es) * 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
JP6153206B2 (ja) * 2011-12-15 2017-06-28 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体
US20140357838A1 (en) 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
MX363119B (es) 2012-05-01 2019-03-11 Novo Nordisk As Composicion farmaceutica.
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20150265710A1 (en) 2012-10-17 2015-09-24 Novo Nordisk A/S Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2014147141A1 (en) * 2013-03-20 2014-09-25 Novo Nordisk A/S Insulin dosing regimen
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
AR100306A1 (es) 2014-02-18 2016-09-28 Novo Nordisk As Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017032797A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JP2018531901A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
TWI747929B (zh) * 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人胰島素或其類似物的醯化衍生物
MA46897A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline dégludec utilisée dans des conditions cardiovasculaires
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
WO2018096163A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
KR102580007B1 (ko) 2016-12-16 2023-09-19 노보 노르디스크 에이/에스 인슐린 함유 약제학적 조성물
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2019218315A1 (en) 2018-02-09 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7410891B2 (ja) 2018-06-26 2024-01-10 ノボ・ノルデイスク・エー／エス 基礎インスリン滴定のための投与推奨を提供するシステム
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20220119730A (ko) 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
CN115867308B (zh) 2020-05-15 2025-12-30 伊莱利利公司 延时作用的酰化胰岛素化合物
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4471053A1 (en) 2022-01-28 2024-12-04 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0506792T3 (da) 1989-12-21 1995-10-09 Novo Nordisk As Insulinpræparat, der indeholder nikotinsyre eller nikotinamid
DK45590D0 (Direct) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
ES2185625T3 (es) 1991-12-20 2003-05-01 Novo Nordisk As Formulacion farmaceutica estabilizada que incluye hormona de crecimiento e histidina.
DK0792290T3 (da) 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
WO1996029344A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
AU3255297A (en) 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0821006B1 (de) 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
CA2283705A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
WO1998042368A1 (en) 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
JP2001518915A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
UA69393C2 (uk) * 1997-10-24 2004-09-15 Ново Нордіск А/С Водорозчинний агрегат похідної інсуліну
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
DK1121144T3 (da) 1998-10-16 2002-09-23 Novo Nordisk As Stabile koncentrerede insulinpræparater til pulmonar indgivelse
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
EP1173482A1 (en) 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
CA2468100A1 (en) 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094956A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
CN1708314A (zh) 2002-10-29 2005-12-14 阿尔萨公司 稳定化的固态多肽微粒
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
CN100422328C (zh) 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
JP2006519253A (ja) 2003-03-04 2006-08-24 ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド 長時間作用性注射用インスリン組成物およびその製造および使用方法
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
AU2005222613B2 (en) 2004-03-12 2009-12-17 Biodel, Inc. Rapid acting drug delivery compositions
CN1993138B (zh) 2004-06-01 2010-12-15 阿雷斯贸易股份有限公司 稳定蛋白质的方法
AU2005272862B2 (en) 2004-08-12 2011-03-10 Merck Sharp & Dohme Corp. Stable pegylated interferon formulation
ES2395035T3 (es) 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
EP1814581B1 (en) 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
WO2006079019A2 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
WO2006082204A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
EP2256129B1 (en) 2006-02-27 2012-05-09 Novo Nordisk A/S Insulin derivatives
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
ES2395738T3 (es) 2006-05-09 2013-02-14 Novo Nordisk A/S Derivado de insulina
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
EP2264065B1 (en) 2017-03-08
CY2013029PI1 (el) 2015-11-04
CA2531988A1 (en) 2005-02-10
US8828923B2 (en) 2014-09-09
CY2013029I1 (Direct) 2024-09-20
EP2264065A2 (en) 2010-12-22
AU2004261353A1 (en) 2005-02-10
CY2013029I2 (el) 2024-09-20
CA2531988C (en) 2016-06-28
EP2107069B1 (en) 2013-01-16
WO2005012347A3 (en) 2005-04-14
WO2005012347A2 (en) 2005-02-10
JP2007523881A (ja) 2007-08-23
IL172980A (en) 2013-10-31
LU92226I2 (fr) 2015-04-29
LU92213I9 (Direct) 2018-11-19
AU2010200497B2 (en) 2014-10-23
CY2013027PI2 (el) 2015-11-04
KR101159559B1 (ko) 2012-06-26
CY2013027I2 (el) 2024-09-20
AU2004261353B2 (en) 2009-12-10
IL172980A0 (en) 2006-06-11
CY2013029PI2 (el) 2015-11-04
CY2013027PI1 (el) 2015-11-04
US20100009899A1 (en) 2010-01-14
US20060183668A1 (en) 2006-08-17
RU2518460C2 (ru) 2014-06-10
EP2107069A3 (en) 2009-11-25
NO2018002I2 (no) 2018-08-20
NO2024003I1 (no) 2024-01-16
BRPI0413276B1 (pt) 2020-03-03
FR13C0038I1 (fr) 2013-08-09
FR13C0035I1 (Direct) 2013-08-09
AU2010200497A1 (en) 2010-03-04
NO340925B1 (no) 2017-07-17
EP2264065A3 (en) 2011-07-27
BE2013C038I2 (Direct) 2023-12-14
LU92213I2 (fr) 2013-08-23
NO2024004I1 (no) 2024-01-16
NO2018003I1 (no) 2018-01-11
CY2013027I1 (el) 2024-09-20
FR13C0035I2 (fr) 2014-03-07
HUS1300033I1 (hu) 2016-08-29
RU2008152033A (ru) 2010-07-10
MXPA06001283A (es) 2006-04-11
BE2013C035I2 (Direct) 2023-12-14
JP4463814B2 (ja) 2010-05-19
NO2018002I1 (no) 2018-01-11
EP1660531A2 (en) 2006-05-31
US7615532B2 (en) 2009-11-10
BRPI0413276B8 (pt) 2021-05-25
BRPI0413276A (pt) 2006-10-10
CY1113850T1 (el) 2015-11-04
LU92226I9 (Direct) 2018-11-19
US20140349925A1 (en) 2014-11-27
EP2107069A2 (en) 2009-10-07
KR20060132543A (ko) 2006-12-21
NO20061026L (no) 2006-03-02

Similar Documents

Publication Publication Date Title
HUS1300033I1 (hu) Új inzulin származékok
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
IL174154A0 (en) Novel glp-1 derivatives
SI2107069T1 (sl) Novi inzulinski derivati
PL1694385T3 (pl) Zestaw do infuzji
PL378559A1 (pl) Pochodne piperydynobenzenosulfonoamidu
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
SI1606277T1 (sl) Derivati imidazol-4-il-etinil-piridina
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
AU2003259457A8 (en) Auto-destructible syringe
IL176562A0 (en) Amidopyrazole derivative
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
SI1706373T1 (sl) Amidoacetonitrilni derivati
GB0329269D0 (en) Syringe
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB2401043B (en) Drug
GB0319793D0 (en) Pyridinylmorpholine derivatives
EP1624073A4 (en) DRUG
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
AU2003280821A8 (en) Beauveriolide derivative
GB0319148D0 (en) Azaquinazoline derivatives
AU2003280822A8 (en) Beauveriolide derivatives
HU0300508D0 (en) Syringe
HU0300481D0 (en) Syringe